{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:58:42Z","timestamp":1777503522019,"version":"3.51.4"},"reference-count":66,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ningbo Science and Technology Innovation 2025 Major Project","award":["2022Z125"],"award-info":[{"award-number":["2022Z125"]}]},{"name":"Natural Science Foundation of Zhejiang Province, China","award":["LY22C180004"],"award-info":[{"award-number":["LY22C180004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Toxoplasma gondii is a globally distributed apicomplexan parasite capable of causing congenital infections and spontaneous abortions in humans. While the parasite-secreted effector proteins TgGRA28 and TgGRA83 are known to mediate virulence or immune modulation, their potential as vaccine targets remains unexplored. Despite its immunomodulatory properties, the role of IL-28B (a type III interferon) in enhancing DNA vaccine efficacy against T. gondii infection remains unclear. Methods: In this study, we constructed eukaryotic expression plasmids pVAX-GRA28, pVAX- GRA83 and pVAX-IL-28B. After transfection into -293-T cell, protein expression encoding TgGRA28 and TgGRA83 was confirmed via indirect immunofluorescence assay (IFA), while IL-28B expression was analyzed by ELISA. Subsequently, C57BL\/6J or IFN\u03b1R1 knockout mice were immunized with single or dual-antigen DNA vaccines, with or without the molecular adjuvant pVAX-IL-28B. Immune responses were assessed through Toxoplasma-specific antibody levels, cytotoxic T lymphocyte (CTL) activity, cytokine profiling (IFN-\u03b3, IL-2, IL-12p40, IL-12p70), and flow cytometric analysis of lymphocyte subsets and dendritic cells (DCs). Protective efficacy was determined by survival rates and brain cyst burden following challenge with 100 or 10 ME49 T. gondii cysts, respectively. Results: Vaccination with pVAX-GRA28 and pVAX-GRA83 elicited robust humoral immune responses with increased T. gondii-specific IgG levels and also Th1-polarized immunity, characterized by elevated IgG2a\/IgG1 ratio, IFN-\u03b3-dominant cytokine responses, and enhanced DCs, CD4+ and CD8+ T-cell activation. The cocktail vaccine conferred superior protection compared to single-antigen formulations, significantly improving survival and reducing cyst formation. Co-administration of pVAX-IL-28B further augmented vaccine-induced immunity, enhancing both cellular and humoral responses. Moreover, these DNA immunization with pVAX-GRA28 and pVAX-GRA83 plus pVAX-IL-28B induced robust protective immunity that was largely independent of type I IFN signaling, consistent with type III IFN biology. Conclusions: Our findings demonstrate that TgGRA28 and TgGRA83 are promising vaccine candidates against toxoplasmosis, capable of inducing protective immunity against acute and chronic infection. Moreover, IL-28B serves as a potent genetic adjuvant, warranting further investigation for its broader application in vaccines targeting apicomplexan parasites.<\/jats:p>","DOI":"10.3390\/vaccines13121180","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:17:23Z","timestamp":1763734643000},"page":"1180","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Protective Efficacy of Two Novel DNA Vaccine Candidates Encoding TgGRA28 and TgGRA83 with an IL-28B Molecular Adjuvant Against Acute and Chronic Toxoplasmosis in Mice"],"prefix":"10.3390","volume":"13","author":[{"given":"Jun","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Radiology, The Affiliated People\u2019s Hospital of Ningbo University, Ningbo 315040, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingqi","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated People\u2019s Hospital of Ningbo University, Ningbo 315040, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated People\u2019s Hospital of Ningbo University, Ningbo 315040, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated People\u2019s Hospital of Ningbo University, Ningbo 315040, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-444-53490-3.00008-X","article-title":"Toxoplasmosis","volume":"114","author":"Halonen","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2352-3018(17)30005-X","article-title":"Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Elsheikha, H.M., Marra, C.M., and Zhu, X.Q. (2021). Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis. Clin. Microbiol. Rev., 34.","DOI":"10.1128\/CMR.00115-19"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.pt.2020.08.005","article-title":"Toxoplasma gondii: An Underestimated Threat?","volume":"36","author":"Milne","year":"2020","journal-title":"Trends Parasitol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/14787210.2018.1483721","article-title":"Management of toxoplasmosis in transplant recipients: An update","volume":"16","author":"Dard","year":"2018","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.amjmed.2004.08.023","article-title":"Toxoplasmosis in pregnancy","volume":"118","author":"Kravetz","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: From animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e00036","DOI":"10.1016\/j.fawpar.2019.e00036","article-title":"Treatment of toxoplasmosis: Current options and future perspectives","volume":"15","author":"Konstantinovic","year":"2019","journal-title":"Food Waterborne Parasitol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1586\/14760584.2015.1098539","article-title":"Recent advances in developing vaccines against Toxoplasma gondii: An update","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1590\/S0074-02762009000200019","article-title":"Vaccines against Toxoplasma gondii: Challenges and opportunities","volume":"104","author":"Jongert","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pt.2019.01.005","article-title":"Advances in the Development of Anti-Toxoplasma gondii Vaccines: Challenges, Opportunities, and Perspectives","volume":"35","author":"Wang","year":"2019","journal-title":"Trends Parasitol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpara.2020.11.001","article-title":"Control of human toxoplasmosis","volume":"51","author":"Smith","year":"2021","journal-title":"Int. J. Parasitol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1586\/14760584.2013.844652","article-title":"Vaccines against Toxoplasma gondii: New developments and perspectives","volume":"12","author":"Zhang","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ten Hoeve, A.L., Rodriguez, M.E., S\u00e4flund, M., Michel, V., Magimel, L., Ripoll, A., Yu, T., Hakimi, M.A., Saeij, J.P.J., and Ozata, D.M. (2024). Hypermigration of macrophages through the concerted action of GRA effectors on NF-\u03baB\/p38 signaling and host chromatin accessibility potentiates Toxoplasma dissemination. mBio, 15.","DOI":"10.1128\/mbio.02140-24"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00263-23","DOI":"10.1128\/msphere.00263-23","article-title":"The Toxoplasma gondii effector GRA83 modulates the host\u2019s innate immune response to regulate parasite infection","volume":"8","author":"Thind","year":"2023","journal-title":"mSphere"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/erv.11.21","article-title":"Trends in vaccine adjuvants","volume":"10","author":"Schijns","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Aggeletopoulou, I., Tsounis, E.P., and Triantos, C. (2022). Molecular Mechanisms Underlying IL-33-Mediated Inflammation in Inflammatory Bowel Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010623"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"M\u00f6ller, A.M., Vettermann, S., Baumann, F., P\u00fctter, M., and M\u00fcller, D. (2025). Trifunctional antibody-cytokine fusion protein formats for tumor-targeted combination of IL-15 with IL-7 or IL-21. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1498697"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1016\/j.vaccine.2014.03.042","article-title":"Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice","volume":"32","author":"Li","year":"2014","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.exppara.2015.12.013","article-title":"Co-administration of interleukins 7 and 15 with DNA vaccine improves protective immunity against Toxoplasma gondii","volume":"162","author":"Chen","year":"2016","journal-title":"Exp. Parasitol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1051\/parasite\/2020021","article-title":"Adjuvantic cytokine IL-33 improves the protective immunity of cocktailed DNA vaccine of ROP5 and ROP18 against Toxoplasma gondii infection in mice","volume":"27","author":"Zhu","year":"2020","journal-title":"Parasite"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Xu, B., Zhang, X., Wang, Y., and Chen, J. (2025). IL-24 Is a Promising Molecular Adjuvant for Enhancing Protective Immunity Induced by DNA Vaccination Against Toxoplasma gondii. Microorganisms, 13.","DOI":"10.3390\/microorganisms13071661"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/imm.13954","article-title":"IFN-\u03bb: Unleashing Its Potential in Disease Therapies From Acute Inflammation Regulation to Cancer Immunotherapy","volume":"176","author":"Tang","year":"2025","journal-title":"Immunology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/blood-2008-11-190520","article-title":"Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity","volume":"113","author":"Morrow","year":"2009","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/intimm\/dxv061","article-title":"IL-28B down-regulates regulatory T cells but does not improve the protective immunity following tuberculosis subunit vaccine immunization","volume":"28","author":"Luo","year":"2016","journal-title":"Int. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Shi, Y., Li, J., Yang, W., and Chen, J. (2023). Protective immunity induced by DNA vaccine containing TgGRA35, TgGRA42, and TgGRA43 against Toxoplasma gondii infection in Kunming mice. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1236130"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arriaza, J., Garaigorta, U., P\u00e9rez, P., L\u00e1zaro-Fr\u00edas, A., Zamora, C., Gastaminza, P., Del Fresno, C., Casasnovas, J.M., Sorzano C\u00d3, S., and Sancho, D. (2021). COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. J. Virol., 95.","DOI":"10.1128\/JVI.02260-20"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41541-022-00581-y","article-title":"A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines","volume":"7","author":"Gomez","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Li, Y., Li, H., Song, X., Ma, Z., Lu, H., Liu, S., Zhao, Y., Tan, M., and Wang, S. (2020). Identification of Toxoplasma gondii Tyrosine Hydroxylase (TH) Activity and Molecular Immunoprotection against Toxoplasmosis. Vaccines, 8.","DOI":"10.3390\/vaccines8020158"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14712598.2018.1413086","article-title":"Moving towards improved vaccines for Toxoplasma gondii","volume":"18","author":"Li","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Rezaei, F., Sharif, M., Sarvi, S., Hejazi, S.H., Aghayan, S., Pagheh, A.S., Dodangeh, S., and Daryani, A. (2019). A systematic review on the role of GRA proteins of Toxoplasma gondii in host immunization. J. Microbiol. Methods, 165.","DOI":"10.1016\/j.mimet.2019.105696"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sun, X., Mei, M., Zhang, X., Han, F., Jia, B., Wei, X., Chang, Z., Lu, H., Yin, J., and Chen, Q. (2014). The extracellular matrix protein mindin as a novel adjuvant elicits stronger immune responses for rBAG1, rSRS4 and rSRS9 antigens of Toxoplasma gondii in BALB\/c mice. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-429"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zhou, J., and Wang, L. (2017). SAG4 DNA and Peptide Vaccination Provides Partial Protection against T. gondii Infection in BALB\/c Mice. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.01733"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.omtn.2025.102536","article-title":"Genetic adjuvants: A paradigm shift in vaccine development and immune modulation","volume":"36","author":"Spunde","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tan, Y., Mu, J., and Chen, J. (2024). IL-36 Gamma: A Novel Adjuvant Cytokine Enhancing Protective Immunity Induced by DNA Immunization with TGIST and TGNSM Against Toxoplasma gondii Infection in Mice. Microorganisms, 12.","DOI":"10.3390\/microorganisms12112258"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e20201314","DOI":"10.1084\/jem.20201314","article-title":"Lessons from Toxoplasma: Host responses that mediate parasite control and the microbial effectors that subvert them","volume":"218","author":"Frickel","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"L\u00fcder, C.G.K. (2024). IFNs in host defence and parasite immune evasion during Toxoplasma gondii infections. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1356216"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2014.04.001","article-title":"The immune potential and immunopathology of cytokine-producing B cell subsets: A comprehensive review","volume":"55","author":"Bao","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zheng, B., Ding, J., Lou, D., Tong, Q., Zhuo, X., Ding, H., Kong, Q., and Lu, S. (2019). The Virulence-Related MYR1 Protein of Toxoplasma gondii as a Novel DNA Vaccine Against Toxoplasmosis in Mice. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00734"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zheng, B., Lou, D., Ding, J., Zhuo, X., Ding, H., Kong, Q., and Lu, S. (2019). GRA24-Based DNA Vaccine Prolongs Survival in Mice Challenged With a Virulent Toxoplasma gondii Strain. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00418"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sun, H.C., Huang, J., Fu, Y., Hao, L.L., Liu, X., and Shi, T.Y. (2021). Enhancing Immune Responses to a DNA Vaccine Encoding Toxoplasma gondii GRA7 Using Calcium Phosphate Nanoparticles as an Adjuvant. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.787635"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1242\/jcs.00683","article-title":"Activation of NF-kappaB by Toxoplasma gondii correlates with increased expression of antiapoptotic genes and localization of phosphorylated IkappaB to the parasitophorous vacuole membrane","volume":"116","author":"Molestina","year":"2003","journal-title":"J. Cell Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1074-7613(04)00076-7","article-title":"T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells","volume":"20","author":"Townsend","year":"2004","journal-title":"Immunity"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.immuni.2016.08.013","article-title":"IRF8 Transcription Factor Controls Survival and Function of Terminally Differentiated Conventional and Plasmacytoid Dendritic Cells, Respectively","volume":"45","author":"Sichien","year":"2016","journal-title":"Immunity"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Li, D., Shen, Y., Li, S., Lu, S., and Zheng, B. (2023). Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB\/c mice against acute toxoplasmosis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1161507"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Li, S., Chu, H., Li, J., Lu, S., and Zheng, B. (2024). A novel mRNA vaccine, TGGT1_278620 mRNA-LNP, prolongs the survival time in BALB\/c mice with acute toxoplasmosis. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.02866-23"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1379\/CSC-138R.1","article-title":"Toxoplasma gondii-derived heat shock protein 70 stimulates maturation of murine bone marrow-derived dendritic cells via Toll-like receptor 4","volume":"11","author":"Aosai","year":"2006","journal-title":"Cell Stress Chaperones"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1128\/IAI.69.4.2589-2595.2001","article-title":"Immunological studies of chronic ocular toxoplasmosis: Up-regulation of major histocompatibility complex class I and transforming growth factor beta and a protective role for interleukin-6","volume":"69","author":"Lyons","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/CMR.00097-13","article-title":"CD4+ T Cells: Guardians of the phagosome","volume":"27","author":"Tubo","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.it.2017.04.002","article-title":"Mechanisms and Dynamics of T Cell-Mediated Cytotoxicity In Vivo","volume":"38","author":"Halle","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Yu, Z., He, K., Cao, W., Aleem, M.T., Yan, R., Xu, L., Song, X., and Li, X. (2022). Nano vaccines for T. gondii Ribosomal P2 Protein With Nanomaterials as a Promising DNA Vaccine Against Toxoplasmosis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.839489"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.pt.2011.03.009","article-title":"Innate responses to Toxoplasma gondii in mice and humans","volume":"27","author":"Pifer","year":"2011","journal-title":"Trends Parasitol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2013Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1038\/mtna.2016.38","article-title":"Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon","volume":"5","author":"Broos","year":"2016","journal-title":"Mol. Therapy Nucleic Acids"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1172\/JCI45416","article-title":"Protective T cell immunity in mice following protein-TLR7\/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets","volume":"121","author":"Lindsay","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Welsh, R.M., Bahl, K., Marshall, H.D., and Urban, S.L. (2012). Type 1 interferons and antiviral CD8 T-cell responses. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002352"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"17480","DOI":"10.1073\/pnas.1904637116","article-title":"Toxoplasma gondii effector TgIST blocks type I interferon signaling to promote infection","volume":"116","author":"Matta","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Hu, Z., Wu, D., Lu, J., Zhang, Y., Yu, S.M., Xie, Y., Li, H., Yang, J., Lai, D.H., and Zeng, K. (2022). Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity. mBio, 13.","DOI":"10.1128\/mbio.02361-22"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood.V99.9.3263","article-title":"Type I interferons produced by dendritic cells promote their phenotypic and functional activation","volume":"99","author":"Montoya","year":"2002","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.4049\/jimmunol.171.7.3385","article-title":"IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities","volume":"171","author":"Mohty","year":"2003","journal-title":"J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.4049\/jimmunol.1202222","article-title":"CD8+ T cells produce the chemokine CXCL10 in response to CD27\/CD70 costimulation to promote generation of the CD8+ effector T cell pool","volume":"191","author":"Peperzak","year":"2013","journal-title":"J. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/12\/1180\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:23:24Z","timestamp":1763735004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/12\/1180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":66,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["vaccines13121180"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13121180","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}